Pfizer (PFE) Invested Capital (2009 - 2026)

Pfizer has disclosed Invested Capital across 18 years of filings, most recently posting $91.0 billion for Q1 2026.

• In Q1 2026, Invested Capital fell 0.53% year-over-year to $91.0 billion; the TTM figure through Mar 2026 stood at $91.0 billion (down 0.53% YoY), while the FY2025 annual figure was $87.4 billion, down 2.15% from the prior year.
• Invested Capital grew to $91.0 billion in Q1 2026, from $87.4 billion in the prior quarter.
• Over the last five years, Invested Capital for PFE reached as high as $102.0 billion in Q2 2023 and fell as low as $83.5 billion in Q2 2022.
• The 5-year median for Invested Capital is $91.4 billion (2025), against an average of $92.4 billion.
• Annual changes were most pronounced in 2022 — Invested Capital soared 153.13% — and 2024, when it slipped 11.32%.
• A 5-year view of Invested Capital shows it stood at $96.7 billion in 2022, then fell by 6.82% to $90.1 billion in 2023, then decreased by 0.93% to $89.3 billion in 2024, then decreased by 2.15% to $87.4 billion in 2025, then gained by 4.13% to $91.0 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $91.0 billion, $87.4 billion, and $94.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.